During Monday’s Current trade, Shares of Fluor Corporation (NEW) (NYSE:FLR), lost -0.75% to $44.90.
Fluor Corporation (FLR) declared that PTT Global Chemical Public Company (PTTGC) has selected a Fluor-led team to perform front-end engineering and design work for its projected petrochemical complex in Belmont County, Ohio. The team comprises Fluor, Technip and SK E&C. Fluor will book the unrevealed contract value into backlog in the third quarter of 2015.
The project will encompass an ethane cracker and derivatives units by leveraging the availability of feedstock from gas taken from the Utica and Marcellus shale formations in the region to create chemical products. Fluor is a leader in the petrochemical engineering, procurement and construction market, and is presently executing engineering, procurement and construction for three major ethane cracker projects in the United States.
Fluor Corporation, through its subsidiaries, provides engineering, procurement, construction, fabrication and modularization, commissioning and maintenance, and project management services worldwide. The company operates in five segments: Oil & Gas, Industrial & Infrastructure, Government, Global Services, and Power. The Oil & Gas segment offers a range of design, engineering, procurement, construction, and project management services to upstream oil and gas production, liquefied natural gas, downstream refining, offshore production, pipeline, chemicals, and petrochemicals industries. It also provides consulting services comprising feasibility studies, process assessment, and project finance structuring and studies.
Shares of RR Donnelley & Sons Co (NASDAQ:RRD), declined -0.60% to $15.03, during its current trading session.
RR Donnelley & Sons Company (RRD) declared that it intends to create three independent, publicly traded companies: one business focused on financial communications and data services; one business focused on publishing and retail-centric print services; and one business focused on customized multichannel communications administration.
Planned Benefits
- Each business to focus on its distinct planned preceding ties, driving opportunities to accelerate growth and enhance long-term value.
- Greater flexibility to execute tailored business strategies and compete in evolving markets.
- Even more focused brand strategy to support each business’s marketing plan.
R.R. Donnelley & Sons Company provides integrated communications solutions to private and public sector clients in the United States and internationally. The company operates through Publishing and Retail Services, Variable Print, Planned Services, and International segments. Its product and service offerings comprise magazines, catalogs, retail inserts, books, directories, and packaging products; commercial and digital print, direct mail, office products, labels, statement printing, and forms; and logistics services, financial print products and related services, print administration products, and digital and creative solutions.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX), during its Monday’s current trading session decreased -0.19% to $225.09.
Biotech company Pharming Group N.V. published its (unaudited) financial report for the six months ended 30 June 2015.
FINANCIAL HIGHLIGHTS
- Revenues from operations raised to €5.2 million (H1 2014: €2.5 million) as a result of substantially raised revenues from product sales of €4.1 million (€2.9 million for Q2), contrast to €1.4 million for H1 2014. Revenues from Ruconest® sales in the US amounted to €3.0 million (€2.4 million for Q2) and in the EU amounted to €1.1 million (€0.5 million for Q2).
- Gross profit raised to €2.9 million (€2.1 million for Q2) from €0.7 million in H1 2014 as a result of sales in the US and a gain on inventory impairments, reflecting the improving yields from sales in the US and direct commercialisation in the EU.
- As result of increasing costs of operations (R&D, General and Administrative and Marketing and Sales), operating result reduced by €0.7 million, to a loss of €6.1 million contrast to a €5.4 million loss for H1 2014. The enhance is mostly a result of the (non-cash) share-based compensation.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
Finally, Nuance Communications Inc. (NASDAQ:NUAN), gained 0.29%, to $17.27.
Nuance Communications, Inc. (NUAN) declared that the Australian Taxation Office (ATO) has accomplished its two-phased deployment of Nuance’s voice biometrics solutions in its call center in an effort to build stronger customer relationships with taxpayers and enhance authentication by replacing intrusive security questioning. With the introduction of its voice biometrics systems, ATO becomes the first organization in Australia to deploy voice biometrics in this manner.
The ATO receives about nine million calls per year from the community, with around 75 percent of these calls requiring an ATO agent to verify the caller’s identity. In addition, the ATO anticipates to receive more than half (4.3) million of these calls within its three-month peak tax period between July and October 2015. Preceding to voice biometrics, when a customer called to conduct a transaction with the ATO, the authentication process involved several steps, putting pressure not only on customers to provide personal details or have the correct documentation in front of them, but also on the ATO’s call center agents, who collectively spent about 75,000 hours each year just trying to verify customers over the phone.
Nuance Communications, Inc. provides voice and language solutions for businesses and consumers worldwide. It offers hosted and on-premise solutions and services that provide platforms to generate and distribute clinical documentation through the use of dictation and transcription features; clinical documentation improvement programs; and speech recognition solutions for radiology, cardiology, pathology, and related specialties enabling healthcare providers to dictate, edit, and sign reports without manual transcription.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
